Compare American Homes 4 Rent Class A (AMH) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Homes 4 Rent Class A vs Sana Biotechnology Inc — how do they compare? American Homes 4 Rent Class A trades at $34.07 (market cap $12.28B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: American Homes 4 Rent Class A is far larger — about 10.9× Sana Biotechnology Inc's market cap, and American Homes 4 Rent Class A pays a 3.87% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| AMH | SANA | |
|---|---|---|
Market Cap | $12.28B | $1.13B |
Sector | Real Estate | Health |
52-Week High | $35.82 | $5.92 |
52-Week Low | $27.38 | $2.68 |
Enterprise Value | $17.35B | $1.05B |
Dividend Yield | 3.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMH (American Homes 4 Rent) trades at $33.87, down 0.76% today, with a bullish technical signal and strong fundamentals. The stock exhibits consistent earnings beats, with Q2 2026 FFO of $0.49 per share exceeding estimates (Zacks Investment Research, July 30, 2026). Revenue growth trends upward, reaching $1.85 billion in 2025, while net income margin improved to 25.53% in 2026. Recent news highlights institutional interest and raised 2026 guidance, supporting positive sentiment.
The outlook for AMH remains favorable due to robust operational performance and analyst consensus, but risks include regulatory changes affecting institutional home buying and high debt levels. With a $36.45 average price target and no sell ratings, Wall Street leans bullish, though investors should monitor housing policy impacts and interest rate sensitivity.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
